

Bao-Hui Han

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4287113/bao-hui-han-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

8,938
citations

28
h-index

94
g-index

149
ext. papers

10,627
ext. citations

5.3
avg, IF

5.29
L-index

#	Paper	IF	Citations
137	The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.. <i>Cancer Medicine</i> , 2022 ,	4.8	1
136	Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study.. <i>Thoracic Cancer</i> , 2022 ,	3.2	1
135	Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update.. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022 , 34, 28-39	3.8	0
134	Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).. <i>BMC Cancer</i> , 2022 , 22, 294	4.8	
133	Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 812555	5.6	
132	Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals.. <i>Frontiers in Cell and Developmental Biology</i> , 2022 , 10, 840466	5.7	
131	The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma.. <i>Cancer Letters</i> , 2022 , 532, 215599	9.9	
130	ASO Visual Abstract: Different Characteristics and Survival Between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma : Differences between P-LCNEC and C-LCNEC.. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	
129	ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.. <i>BMC Medicine</i> , 2022 , 20, 170	11.4	1
128	Novel blood-based hypomethylation of SH3BP5 is associated with very early-stage lung adenocarcinoma. <i>Genes and Genomics</i> , 2021 , 1	2.1	0
127	Interstitial lung abnormalities: What do we know and how do we manage?. <i>Expert Review of Respiratory Medicine</i> , 2021 , 15, 1551-1561	3.8	
126	FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor. <i>Life Sciences</i> , 2021 , 268, 119022	6.8	1
125	Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021 , 11, 652560	5.3	3
124	Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 643-652	8.9	30
123	Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery. <i>Lung Cancer</i> , 2021 , 154, 124-130	5.9	0
122	Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. <i>Respiratory Research</i> , 2021 , 22, 145	7.3	0
121	Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 665484	5.3	1

120	Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial. <i>Thoracic Cancer</i> , 2021 , 12, 2345-2351	3.2	1
119	EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study. <i>Clinical Lung Cancer</i> , 2021 , 22, e395-e404	4.9	1
118	Clinical significance of visceral pleural and lymphovascular invasion in surgically resected adenocarcinoma lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2021 , 59, 617-623	3	1
117	Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2261-2274	7.4	5
116	Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring or mutation. <i>Oncotarget</i> , 2021 , 10, 1865670	7.2	1
115	PLGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/ β -catenin pathway. <i>Cancer Cell International</i> , 2021 , 21, 18	6.4	0
114	Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis. <i>Cell Death and Disease</i> , 2021 , 12, 170	9.8	8
113	DUBR suppresses migration and invasion of human lung adenocarcinoma cells via ZBTB11-mediated inhibition of oxidative phosphorylation. <i>Acta Pharmacologica Sinica</i> , 2021 ,	8	4
112	Utility and Safety of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Diagnosis of Isolated Mediastinal Masses. <i>Journal of Multidisciplinary Healthcare</i> , 2021 , 14, 2047-2052	2.8	
111	Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations. <i>Frontiers in Oncology</i> , 2021 , 11, 681429 ^{5.3}	5.3	0
110	hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527. <i>Cell Death and Disease</i> , 2021 , 12, 807	9.8	10
109	ctDNA-Profilng-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among -Negative NSCLC Patients. <i>Frontiers in Genetics</i> , 2021 , 12, 723670	4.5	3
108	Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. <i>International Immunopharmacology</i> , 2021 , 98, 107734	5.8	3
107	Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021 , 12, 708558	8.4	3
106	Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021 , 12, 732125	8.4	2
105	Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. <i>Cancer Biology and Medicine</i> , 2021 ,	5.2	6
104	Methylation in Peripheral Blood as A Potential Marker for the Early-stage Lung Cancer: A Case-control Study in Chinese Population. <i>Biomarkers</i> , 2021 , 1-15	2.6	
103	Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis. <i>Targeted Oncology</i> , 2020 , 15, 337-345	5	1

102	Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study. <i>Targeted Oncology</i> , 2020 , 15, 175-184	5	8
101	Does surgically resected small-cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?. <i>Thoracic Cancer</i> , 2020 , 11, 1239-1244	3.2	5
100	CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 1049	5.3	2
99	Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer. <i>Annals of Palliative Medicine</i> , 2020 , 9, 1681-1687	1.7	1
98	A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab. <i>Oncolmmunology</i> , 2020 , 9, 1731072	7.2	18
97	Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. <i>Cancer Medicine</i> , 2020 , 9, 2621-2630	4.8	5
96	Serum TNFR1I: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 4150-4156	5.6	1
95	The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303). <i>Oncologist</i> , 2020 , 25, e870-e874	5.7	15
94	Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China. <i>Clinical Lung Cancer</i> , 2020 , 21, e355-e362	4.9	4
93	Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 582-589	7.3	4
92	Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells. <i>Acta Pharmacologica Sinica</i> , 2020 , 41, 1357-1365	8	9
91	Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 401-406	4.9	14
90	Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery. <i>Lung Cancer</i> , 2020 , 141, 72-77	5.9	5
89	Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. <i>Journal of International Medical Research</i> , 2020 , 48, 300060519887275	1.4	8
88	The Association Between RAPSN Methylation in Peripheral Blood and Early Stage Lung Cancer Detected in Case-Control Cohort. <i>Cancer Management and Research</i> , 2020 , 12, 11063-11075	3.6	4
87	Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2020 , 10, 556194	5.3	4
86	Tumour mutational burden in treatment-resistant tumours. <i>Lancet Oncology, The</i> , 2020 , 21, e551	21.7	2
85	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1636-1646	8.9	75

84	Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy. <i>Journal of Immunotherapy</i> , 2020 , 43, 189-195	5	9
83	Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2020 , 2020, 8811487	4.5	0
82	Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies. <i>International Journal of Cancer</i> , 2020 , 146, 3124-3133	7.5	23
81	Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line. <i>Frontiers in Oncology</i> , 2019 , 9, 886	5.3	15
80	Development and validation of a predictive model for the diagnosis of solid solitary pulmonary nodules using data mining methods. <i>Journal of Thoracic Disease</i> , 2019 , 11, 950-958	2.6	7
79	Adjuvant Chemotherapy Improves Survival in Surgically Resected Stage IB Squamous Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2019 , 107, 1683-1689	2.7	2
78	Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy. <i>Annals of Surgical Oncology</i> , 2019 , 26, 2392-2400	3.1	5
77	Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. <i>Targeted Oncology</i> , 2019 , 14, 169-178	5	9
76	Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells. <i>BMC Medical Genomics</i> , 2019 , 12, 38	3.7	18
75	Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases. <i>Journal of Cardiothoracic Surgery</i> , 2019 , 14, 63	1.6	1
74	Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study. <i>Lung Cancer</i> , 2019 , 130, 18-24	5.9	4
73	Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer. <i>Advanced Science</i> , 2019 , 6, 1900721	13.6	19
72	Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment. <i>Clinical Lung Cancer</i> , 2019 , 20, e631-e637	4.9	3
71	Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients. <i>Lung Cancer</i> , 2019 , 135, 138-144	5.9	7
70	Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma. <i>Targeted Oncology</i> , 2019 , 14, 423-431	5	0
69	Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma. <i>Molecular Diagnosis and Therapy</i> , 2019 , 23, 773-779	4.5	3
68	Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. <i>Oncologist</i> , 2019 , 24, 157-e64	5.7	37
67	Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	36

66	Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. <i>International Journal of Cancer</i> , 2019 , 144, 2880-2886	7.5	14
65	OCT4&SOX2-specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem-like cells in vitro and treating drug-resistant lung cancer mice in vivo. <i>Journal of Cellular Physiology</i> , 2019 , 234, 6758-6768	7	7
64	Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening. <i>Lung Cancer</i> , 2018 , 117, 20-26	5.9	34
63	Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?. <i>Lung Cancer</i> , 2018 , 117, 27-31	5.9	9
62	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018 , 118, 654-661	8.7	121
61	Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas. <i>Cancer</i> , 2018 , 124, 2399-2406	6.4	12
60	Predictors of recurrence and survival of pathological T1N0M0 invasive adenocarcinoma following lobectomy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1015-1023	4.9	11
59	Utility of endobronchial ultrasound-guided transbronchial needle aspiration in diagnosing non-specific inflammatory intrathoracic lymphadenitis. <i>Clinical Respiratory Journal</i> , 2018 , 12, 691-698	1.7	3
58	High-resolution Computed Tomography Features Distinguishing Benign and Malignant Lesions Manifesting as Persistent Solitary Subsolid Nodules. <i>Clinical Lung Cancer</i> , 2018 , 19, e75-e83	4.9	22
57	A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, 27-34	4.9	17
56	Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018 , 156, 2006-2015.e2	1.5	6
55	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 1569-1575	13.4	218
54	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018 , 7, 428-436	4.4	5
53	Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018 , 155, 1227-1235.e2	1.5	32
52	Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment. <i>Cancer Biology and Medicine</i> , 2018 , 15, 443-451	5.2	19
51	Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer. <i>Lung Cancer</i> , 2018 , 125, 245-252	5.9	9
50	Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy. <i>Technology in Cancer Research and Treatment</i> , 2018 , 17, 1533033818801809	2.7	14
49	Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review. <i>Targeted Oncology</i> , 2018 , 13, 631-639	5	2

48	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 122, 32-37	5.9	27
47	Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. <i>Lung Cancer</i> , 2017 , 104, 119-125	5.9	31
46	Predicting the recurrence risk factors and clinical outcomes of peripheral pulmonary adenocarcinoma ≥ 1 cm with wedge resection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1043-1051	4.9	7
45	Endobronchial Ultrasound Elastography for Evaluation of Intrathoracic Lymph Nodes: A Pilot Study. <i>Respiration</i> , 2017 , 93, 327-338	3.7	28
44	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017 , 2, e000174	6	3
43	Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. <i>International Journal of Cancer</i> , 2017 , 141, 1249-1256	7.5	63
42	Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations. <i>International Journal of Cancer</i> , 2017 , 140, 1645-1652	7.5	20
41	Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 663-672	8.9	67
40	Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology, The</i> , 2017 , 18, S3	21.7	12
39	Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma. <i>Oncotarget</i> , 2017 , 8, 7050-7058	3.3	16
38	Primary thoracic extraskeletal osteosarcoma: a case report and literature review. <i>Journal of Thoracic Disease</i> , 2017 , 9, E1088-E1095	2.6	12
37	EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. <i>Lung Cancer</i> , 2017 , 113, 37-44	5.9	70
36	Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 347-353	8.9	38
35	Association between polymorphisms of autophagy pathway and responses in non-small cell lung cancer patients treated with platinum-based chemotherapy. <i>Yi Chuan = Hereditas / Zhongguo Yi Chuan Xue Hui Bian Ji</i> , 2017 , 39, 250-262	1.4	3
34	Transcriptional profiling revealed the anti-proliferative effect of MFN2 deficiency and identified risk factors in lung adenocarcinoma. <i>Tumor Biology</i> , 2016 , 37, 8643-55	2.9	7
33	EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. <i>Lung Cancer</i> , 2016 , 96, 87-92	5.9	53
32	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 1325-30	4.9	16
31	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016 , 17, 309-14	4.9	12

30	MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma. <i>Oncotarget</i> , 2016 , 7, 83051-83059	3.3	8
29	Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study. <i>Chinese Clinical Oncology</i> , 2016 , 5, 79	2.3	4
28	Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma. <i>Journal of Thoracic Disease</i> , 2016 , 8, 2610-2616	2.6	37
27	Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 2031-40	4.9	28
26	Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer. <i>Gene</i> , 2016 , 591, 58-64	3.8	28
25	Effects of para-toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial. <i>Lung Cancer</i> , 2016 , 98, 43-50	5.9	11
24	RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer. <i>Acta Pharmacologica Sinica</i> , 2016 , 37, 1490-1498	8	6
23	ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1682-9	8.9	127
22	Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma. <i>Medical Oncology</i> , 2015 , 32, 132	3.7	38
21	Placental growth factor promotes metastases of non-small cell lung cancer through MMP9. <i>Cellular Physiology and Biochemistry</i> , 2015 , 37, 1210-8	3.9	27
20	Establishment and management of a lung cancer biobank in Eastern China. <i>Thoracic Cancer</i> , 2015 , 6, 58-63	3.2	3
19	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2197-204	2.2	224
18	Determining factors in diagnosing pulmonary sarcoidosis by endobronchial ultrasound-guided transbronchial needle aspiration. <i>Annals of Thoracic Surgery</i> , 2015 , 99, 441-5	2.7	25
17	Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. <i>Tumor Biology</i> , 2014 , 35, 4921-8	2.9	14
16	XPA gene rs1800975 single nucleotide polymorphism and lung cancer risk: a meta-analysis. <i>Tumor Biology</i> , 2014 , 35, 6607-17	2.9	13
15	A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. <i>Scientific Reports</i> , 2014 , 4, 4813	4.9	18
14	Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma. <i>Acta Pharmacologica Sinica</i> , 2014 , 35, 373-80	8	5
13	NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis. <i>Tumor Biology</i> , 2013 , 34, 3967-79	2.9	8

12	Endobronchial ultrasound-guided transbronchial needle aspiration in diagnosing intrathoracic tuberculosis. <i>Annals of Thoracic Surgery</i> , 2013 , 96, 2021-7	2.7	63
11	Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. <i>European Journal of Cancer</i> , 2013 , 49, 3111-21	7.5	58
10	Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations. <i>Thoracic Cancer</i> , 2013 , 4, 433-439	3.2	1
9	Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. <i>Lancet Oncology</i> , 2012 , 13, 466-75	21.7	189
8	Lung cancer and benign lung diseases in patients with serious vitamin D deficiency in eastern China. <i>Thoracic Cancer</i> , 2012 , 3, 303-306	3.2	5
7	Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. <i>PLoS ONE</i> , 2012 , 7, e33200	3.7	28
6	Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1781-1789	8.9	14
5	A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1104-9	8.9	66
4	First 30 endobronchial ultrasound-guided transbronchial needle aspirations: a single institution's early experience. <i>Chinese Medical Journal</i> , 2011 , 124, 1818-23	2.9	4
3	Role of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of bronchogenic carcinoma: Experience of a single institution in China. <i>Thoracic Cancer</i> , 2010 , 1, 28-34	3.2	10
2	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. <i>New England Journal of Medicine</i> , 2009 , 361, 947-57	59.2	6253
1	Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. <i>Clinical Cancer Research</i> , 2007 , 13, 5455-62	12.9	103